Identifying Signature Biomarkers of Lung Adenocarcinoma Using Integrative Epigenomics, Transcriptomics Analysis
Selective KRAS G12C Inhibitor MK-1084 as Monotherapy, in Combination With Pembrolizumab: A Phase 1 Dose-Escalation Study
Adagrasib Plus Cetuximab Shows Promise for Patients With KRAS-Mutated Colorectal Cancer